Market Context — Why This Technology, Why Now

The biopharmaceutical industry is experiencing unprecedented growth in gene and cell therapies, driven by breakthroughs in genomics and personalized medicine. Regulatory bodies are increasingly scrutinizing the safety profiles of novel drug delivery systems, pushing for non-viral alternatives with reduced immunogenicity and toxicity. This technology directly addresses these demands, enabling developers to meet stringent safety standards while accelerating drug pipelines, positioning them to capture a significant share of the rapidly expanding global market for advanced therapeutics.

Key Competitive Advantages
01

Increases nucleic acid introduction efficiency by up to 3x, accelerating gene therapy development for intractable diseases.

02

Reduces cellular toxicity risk by approximately 80% (1/5th), significantly enhancing gene therapy safety.

03

Ensures stable quality and mass production through patented chemical structure and manufacturing method, optimizing R&D and production costs.

Market Opportunity
Gene Therapy Drug Market
$4.5B globally (AI est.)
Gene therapy is a cutting-edge medical field offering revolutionary treatments for cancer and genetic diseases, where safety and efficient nucleic acid delivery are key to success. This technology overcomes non-viral vector challenges, driving market expansion.
Major pharmaceutical companies developing gene therapies Biotech firms specializing in genetic disease treatments Contract development and manufacturing organizations (CDMOs) for advanced therapies
Nucleic Acid Drugs & mRNA Vaccine Market
$2.0B globally (AI est.)
mRNA vaccines and nucleic acid drugs gained prominence during the COVID-19 pandemic, with their technological foundations rapidly evolving. This technology ensures stable nucleic acid transport and highly efficient intracellular delivery, accelerating new drug development.
Vaccine developers and manufacturers Pharmaceutical companies focused on RNA therapeutics Biotech startups innovating in nucleic acid delivery
Cell & Regenerative Medicine Market
$1.0B globally (AI est.)
The cell and regenerative medicine sector critically relies on technologies for introducing genes into cells. This technology achieves both high introduction efficiency and low cellular toxicity, playing a vital role in enhancing the safety and practicality of cell therapies.
Regenerative medicine companies Cell therapy developers Research institutions focused on stem cell applications
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a specific chemical structure of modified polyethyleneimine and its manufacturing method, defined by 7 clear claims. It has demonstrated strong differentiation from 8 prior art documents, establishing its uniqueness and robust legal standing.

Competitive White Space

This patent primarily covers the modified polyethyleneimine structure and its manufacturing. White space exists in developing novel formulations with specific targeting ligands, integrating this PEI into advanced drug delivery devices, or exploring its use as a scaffold for non-nucleic acid therapeutic agents.

Economic Impact
~$2.0M/year estimated development cost reduction per facility (est.).
estimated ROI · USD · AI analysis
ROI Calculation Logic

In gene therapy drug development, toxicity evaluation in non-clinical trials is a major challenge. This technology significantly reduces cellular toxicity, lowering the risk of safety-related failures in late-stage development and potentially avoiding costly clinical trial phase repetitions. Assuming an average cost of $100M (AI est.) for clinical phases I-III, with safety-related failures accounting for 20% of that, a 10% reduction in such failures due to this technology could result in an estimated annual development cost reduction of $2.0M (AI est.) ($100M × 20% × 10%).

Speed to Market
4× faster than in-house development
This technology, encompassing a specific chemical structure of modified polyethyleneimine and its manufacturing method, is already established, with its effects concretely indicated in the patent specification. Adopting companies can significantly shorten basic research and compound discovery phases, moving directly to performance verification and application development, thereby accelerating time-to-market. Specifically, it enables rapid acquisition of initial evaluation data for nucleic acid introduction efficiency and cellular toxicity in non-clinical trials, allowing for early progression into development stages.
Competitive Positioning

X: Nucleic Acid Introduction Efficiency
Y: Cellular Toxicity Reduction

Business Models & Applications
🧪 Gene Therapy & Nucleic Acid Drug Development License
Licensing this technology could enable pharmaceutical companies to shorten development timelines for new gene therapies and nucleic acid drugs, accelerating market entry. It offers high safety as a non-viral vector.
💊 DDS Material Supply Model
Supplying this modified polyethyleneimine as a foundational material for Drug Delivery Systems (DDS) could contribute to the development of diverse biopharmaceuticals, establishing a revenue stream for material manufacturers.
🔬 Nucleic Acid Introduction Contract Service
By leveraging this technology to offer contract nucleic acid introduction services to cells, research and development can be streamlined, securing stable demand from pharmaceutical and biotech companies.
Adjacent Application Opportunities
🧬 Genome Editing & Bio Research
Genome Editing Tool Delivery
This modified polyethyleneimine could be applied as an intracellular delivery carrier for genome editing tools like CRISPR/Cas9. It offers higher efficiency and lower toxicity compared to conventional delivery methods, accelerating research from basic science to therapeutic applications.
🧪 Diagnostic Agents & Biosensors
Diagnostic Probe Delivery
In diagnostics, this technology could efficiently deliver nucleic acid probes into cells or tissues to detect specific biomarkers. It has the potential to contribute to the development of highly sensitive and selective diagnostic systems, aiding in early disease detection and personalized medicine advancements.
🍔 Cultured Meat & Cellular Agriculture
Growth Factor Delivery for Cell Culture
The cultured meat and cellular agriculture sectors require technologies to introduce growth factors into cells to promote proliferation and differentiation. Applying this technology could enable efficient and safe cell culture, potentially reducing production costs and improving product quality.
Integration Roadmap — Estimated 22-Month Deployment
Phase 1: Basic Technology Verification & Compatibility
Duration: 4 months
Conduct detailed verification of the technology's synthesis protocol and assess its compatibility with the adopting company's existing production facilities. Perform small-scale trial synthesis and initial physicochemical property evaluation.
Phase 2: Production Process Optimization & Non-Clinical Evaluation
Duration: 8 months
Based on the optimized manufacturing process, establish conditions for scale-up production and build a quality control system. Manufacture quantities required for non-clinical trials, aiming to acquire initial safety and efficacy evaluation data.
Phase 3: Clinical Application Review & Mass Production Preparation
Duration: 10 months
While preparing for transition to mass production, formulate a clinical trial plan for drug candidates utilizing this technology. Coordinate with regulatory authorities and clinical trial partners to finalize preparations for market entry.
Technical Feasibility
This technology, concerning a modified polyethyleneimine with a specific chemical structure and its manufacturing method, is well-established within chemical synthesis. It can be integrated into production lines using existing organic synthesis equipment and standard chemical processes, eliminating the need for substantial new capital investment. The patent claims suggest specific synthesis conditions and materials, making reagent procurement and process optimization the primary integration steps.
Success Scenario
If adopted, this technology could significantly expand the options for non-viral vectors in gene therapy and nucleic acid drug development. Improved safety may reduce clinical trial dropout risks, potentially shortening development timelines. This is estimated to reduce the average development period by approximately 1.5 years, enabling earlier delivery of innovative medicines to patients.
Patent Record
APPLICATION NO.
特願2019-090841
REGISTRATION NO.
7305158
FILING DATE
2019年05月13日
GRANT DATE
2023年06月30日
EXPIRATION DATE
2039年05月13日
PATENT HOLDER
国立大学法人滋賀医科大学
Examination History
2022年05月10日
出願審査請求書
2023年01月24日
拒絶理由通知書
2023年03月22日
意見書
2023年03月22日
手続補正書（自発・内容）
2023年05月23日
特許査定